United States Growth Hormone Deficiency Treatment Market Set for Strong Expansion Driven by Innovative Therapies & Rising Prevalence 2025 | Top key players - Pfizer Inc., Sandoz AG, Novo Nordisk Inc.

Market Size and Growth:

The Global Growth Hormone Deficiency Treatment Market size reached US$ 6.9 billion in 2024 and is expected to reach US$ 9.2 billion by 2032, growing at a CAGR of 12.1% during the forecast period 2025-2032.

The Growth Hormone Deficiency Treatment Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/growth-hormone-deficiency-market?sz

The Growth Hormone Deficiency Treatment Market refers to the global industry focused on therapies and medications designed to manage growth hormone deficiency (GHD), a condition where the body produces insufficient growth hormone. This market includes recombinant human growth hormone (rhGH) therapies, emerging long-acting formulations, diagnostic advancements, and supportive healthcare services, addressing pediatric and adult patients worldwide.

Recent Key Developments of United States (U.S):

FDA Approval of a Long-Acting Treatment for Adults: The U.S. Food and Drug Administration (FDA) approved Skytrofa (lonapegsomatropin-tcgd) for the once-weekly treatment of GHD in adults. This approval, effective as of July 29-31, 2025, expands the use of a drug previously approved for pediatric patients.

Long-Term Efficacy and Safety Data for Lonapegsomatropin: Final results from the "enliGHten" clinical trial were published in March 2025, demonstrating sustained height improvements for up to six years in children with GHD who were treated with once-weekly lonapegsomatropin. The study confirmed the drug's long-term safety and efficacy.

Continued Clinical Trials: Ongoing, post-marketing studies are underway to further assess the long-term safety and effectiveness of SKYTROFA (lonapegsomatropin) in a real-world setting for pediatric patients. These studies are non-interventional and observational, providing data on the drug's use in routine clinical care.

Focus on Long-Acting Formulations: The market continues to shift towards long-acting formulations. Developments like the FDA approval of once-weekly Skytrofa for adults and the long-term clinical data reinforce the trend of reducing injection frequency for improved patient convenience and adherence.

Market Growth Projections: The U.S. GHD treatment market is projected to grow significantly, with one report from March 2025 forecasting a U.S. market size of around USD 7.94 billion by 2034, with a CAGR of 11.19% from 2025. This growth is driven by increasing awareness, advancements in diagnostic technologies, and the introduction of innovative therapies.

List of the Key Players in the Growth Hormone Deficiency Treatment Market:

Pfizer Inc.
Sandoz AG
Novo Nordisk Inc.
Eli Lilly and Company
Ferring
Genentech, Inc.
Merck KGaA (EMD Serono, Inc.)
Reliance Life Sciences
AnkeBio Co., Ltd
Omicron Pharma.

Emerging Market Players:

Genexine, Inc.
JCR Pharmaceuticals Co., Ltd.
Ascendis Pharma
BioNTech SE.
Philogen S.p.A.

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=growth-hormone-deficiency-market

Segments Covered in the Growth Hormone Deficiency Treatment Market:

By Type: Pediatric, Adult.

By Treatment: Pharmacological Therapy, Recombinant Human Growth Hormone Therapy, Human Pituitary Gland Extracts, Others.

By Route of Administration: Intravenous, Intramuscular, Others.

By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/growth-hormone-deficiency-market?sz

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Growth Hormone Deficiency Treatment market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Growth Hormone Deficiency Treatment Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Growth Hormone Deficiency Treatment market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Growth Hormone Deficiency Treatment Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Growth Hormone Deficiency Treatment Market in 2025?
◆ What is the projected growth rate of the Growth Hormone Deficiency Treatment Market through 2033?
◆ Who are the key players in the Growth Hormone Deficiency Treatment Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.